Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.36 |
| ▸ | TGM2 | P21980 | 4/20 | 0.36 |
| ▸ | TYR | P14679 | 2/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGAV | P06756 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20465446 | 1.00 | FOLH1 (0.36) | FOLH1TGM2TYRSIRT2SIRT1 | |
| SCHEMBL18451517 | 0.94 | FOLH1 (0.33) | FOLH1TGM2TYRSIRT2SIRT1 | |
| SCHEMBL18452620 | 0.91 | L3MBTL1 (0.35) | FOLH1TYR | |
| SCHEMBL20465431 | 0.91 | L3MBTL1 (0.35) | FOLH1TYR | |
| SCHEMBL23627653 | 0.90 | FOLH1 (0.36) | FOLH1TGM2TYRSIRT2SIRT1 | |
| SCHEMBL20465444 | 0.89 | FOLH1 (0.31) | FOLH1 | |
| SCHEMBL20465423 | 0.89 | FOLH1 (0.31) | FOLH1 | |
| SCHEMBL18476659 | 0.86 | TGM2 (0.44) | FOLH1TGM2TYRSIRT2SIRT1 | |
| SCHEMBL21469698 | 0.86 | FOLH1 (0.38) | FOLH1TGM2TYRSIRT2SIRT1 | |
| SCHEMBL30799800 | 0.83 | FOLH1 (0.40) | FOLH1TGM2TYRSIRT2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759444-B2 | Methods for cancer and immunotherapy using prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-09-19 | — | — | US | disclosed |
| US-20210206787-A1 | PRODRUGS OF GLUTAMINE ANALOGS | Ústav organické chemie a biochemie AV CR, v.v.i. (CZ) | 2021-07-08 | — | — | US | disclosed |
| US-20180221337-A1 | METHODS AND COMPOSITIONS FOR TREATING METABOLIC REPROGRAMMING DISORDERS | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2018-08-09 | — | — | US | disclosed |
| US-20180222930-A1 | PRODRUGS OF GLUTAMINE ANALOGS | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2018-08-09 | — | — | US | disclosed |
| US-20180221395-A1 | METHODS FOR CANCER AND IMMUNOTHERAPY USING PRODRUGS OF GLUTAMINE ANALOGS | UNIV JOHNS HOPKINS (US) | 2018-08-09 | — | — | US | disclosed |
| US-20180193362-A1 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206787-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | FOLH1 44/4885TGM2 97/4885TYR 3163/4885 |
| US-20180193362-A1 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS | GLUL, GLS2, SLC1A2 | FOLH1 1528/4885TGM2 107/4885TYR 2384/4885 |
| US-11759444-B2 | Methods for cancer and immunotherapy using prodrugs of glutamine analogs | ADORA2A, ADORA1, ADORA2B | FOLH1 189/4885TGM2 416/4885TYR 2869/4885 |
| US-20180221337-A1 | METHODS AND COMPOSITIONS FOR TREATING METABOLIC REPROGRAMMING DISORDERS | GLS, GLS2, PC | FOLH1 1804/4885TGM2 302/4885TYR 3362/4885 |
| US-20180222930-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | FOLH1 403/4885TGM2 57/4885TYR 2744/4885 |
| US-20180221395-A1 | METHODS FOR CANCER AND IMMUNOTHERAPY USING PRODRUGS OF GLUTAMINE ANALOGS | ADORA2A, ADORA1, ADORA2B | FOLH1 189/4885TGM2 416/4885TYR 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.